Peptides for Women Over 40: Perimenopause and Honest Answers
Perimenopause brings real changes and a flood of peptide marketing. Here is where approved peptide medicines genuinely fit, which treatments have stronger evidence, and what to ask before anything else.
Somewhere in your forties, the rules seem to change. Sleep gets lighter, weight settles in new places, energy dips, periods do unpredictable things, and your phone starts showing you peptide injections promising to fix all of it. Some of those symptoms have excellent, well-studied treatments. Very few of those treatments are the peptides in the ads.
The short version
- Many symptoms women notice after 40 are linked to perimenopause, the transition before periods stop. In the US, the average age of menopause is 52, and the transition usually begins between 45 and 55.
- For hot flashes and night sweats, menopause hormone therapy is the most effective treatment according to The Menopause Society, and FDA has approved a non-hormonal option too. Neither is a peptide.
- Some FDA-approved peptide medicines are relevant to women over 40 for specific conditions: GLP-1-based medicines for weight management, bremelanotide for a defined type of low desire in premenopausal women, and teriparatide or abaloparatide for postmenopausal osteoporosis.
- The unapproved peptides marketed for energy, sleep, skin or "hormone balance" have not been tested in trials of perimenopausal women for those purposes, as far as we are aware, and their legal status has been in flux.
- A good consultation starts with your symptoms, history and labs, not with a product list, and it may not end with a peptide at all.
This article is written for women trying to separate real options from marketing. It covers what is happening in your body, which treatments have strong evidence, where approved peptide medicines genuinely fit, and the questions to ask before anyone sells you an unapproved one.
What's actually changing after 40
Perimenopause is the years-long run-up to menopause, which is defined as 12 months without a period. According to the National Institute on Aging, most women begin the transition between ages 45 and 55, the average age of menopause in the US is 52, and symptoms can last for several years, with wide variation between women. For some, changes start in the early forties.
During this time estrogen and progesterone don't simply decline; they swing, sometimes sharply. That variability helps explain why symptoms can come and go and why they are so easy to misattribute. Common experiences include:
- irregular periods, heavier or lighter bleeding;
- hot flashes and night sweats;
- poor or broken sleep;
- mood changes and irritability;
- vaginal dryness and changes in desire;
- changes in body composition, including more weight around the middle and a gradual loss of muscle;
- forgetfulness or trouble concentrating.
Not every symptom in your forties is hormonal, though. Thyroid disease, iron deficiency from heavy periods, sleep apnea, depression, medication side effects and blood sugar problems all become more common and can look very similar. Finding the right cause is the first job of any clinician you see, and it is covered in our overview of hormone health for women.
Worth knowing
Because hormone levels fluctuate so much during perimenopause, a single blood test often can't confirm or rule it out. Diagnosis is usually based on your age, cycle changes and symptoms. Labs are still valuable, but mainly to look for the other conditions above. Our guide to lab work before peptide therapy explains which tests tend to be useful.
The treatments with the strongest evidence aren't peptides
It would be dishonest to write about perimenopause without starting here.
Menopause hormone therapy
The Menopause Society (formerly the North American Menopause Society), in its 2022 hormone therapy position statement, concluded that hormone therapy remains the most effective treatment for hot flashes and night sweats and for genitourinary symptoms of menopause, and that it has been shown to prevent bone loss and fracture. It also concluded that for most healthy women under 60 or within 10 years of menopause, without contraindications, the benefits outweigh the risks. That decision is individual and depends on your history, including breast cancer, blood clots, stroke and heart disease, and it deserves a proper conversation.
Non-hormonal options
For women who can't or don't want to use hormones, there are non-hormonal prescription options for hot flashes. One is fezolinetant (Veozah), which FDA approved in 2023 for moderate to severe hot flashes due to menopause; FDA later added a warning about rare but serious liver injury, which means liver blood tests are part of using it. Several other medicines are used as well. None of these is a peptide either.
The unglamorous foundations
Strength training, adequate protein, alcohol reduction and treating sleep problems have real effects on body composition, bone, mood and energy in midlife. They don't make good advertisements. They do make a difference, and they make any medication that is added work better.
Where FDA-approved peptide medicines genuinely fit
Several approved medicines are peptides, and some are directly relevant to women over 40. Each is approved for a specific condition, with known side effects and monitoring. Our full list is in the peptide medicines that are FDA-approved.
| Concern | Approved peptide medicine | Who it's approved for |
|---|---|---|
| Weight | Semaglutide (Wegovy), tirzepatide (Zepbound) | Adults who meet specific weight criteria, alongside diet and activity |
| Low sexual desire | Bremelanotide (Vyleesi) | Premenopausal women with acquired, generalized hypoactive sexual desire disorder; not postmenopausal women |
| Bone | Teriparatide, abaloparatide | Postmenopausal women with osteoporosis at high risk of fracture, among others |
Weight and body composition
Midlife weight gain is partly hormonal and partly about muscle loss, sleep and life. GLP-1-based medicines have large trials behind them for weight management in eligible adults. They also have common gastrointestinal side effects, and weight loss on them can include muscle as well as fat, which matters more as you age. Read our GLP-1 weight loss guide and the article on protecting muscle on a GLP-1 before deciding.
Desire
Bremelanotide's approval covers premenopausal women only, which can include women in early perimenopause who still have periods. It is not approved after menopause, where low desire often has different drivers such as vaginal dryness or pain, which have their own treatments. We look at the details in PT-141 (bremelanotide): what it is approved for.
Bone
Bone loss speeds up around menopause. Teriparatide and abaloparatide are peptide medicines used for osteoporosis in people at high fracture risk, usually managed alongside a specialist and after a bone density scan. They are not "bone health" boosters for women with normal bones.
The unapproved peptides marketed to women
Women in their forties are a major target for peptide marketing, usually under promises of better sleep, more energy, glowing skin, easier fat loss or "balanced hormones". The compounds offered commonly include growth-hormone secretagogues such as CJC-1295 and ipamorelin, BPC-157, GHK-Cu, MOTS-c and sermorelin.
Three things are true of this group as a whole:
- We are not aware of trials testing them in perimenopausal women for the symptoms they are marketed for. Most of the evidence is from animals, small studies in other populations, or none at all.
- None of them treats the underlying hormone shift. "Hormone balancing" is a marketing phrase, not a description of what these compounds do.
- Their regulatory status has been in flux. In July 2026, an FDA advisory committee narrowly voted to recommend several peptides, including BPC-157 and MOTS-c, for the compounding bulks list. Those votes are non-binding, and as of August 2026 legal analyses indicated these peptides still couldn't lawfully be compounded from bulk. Rules change, so verify the current position with FDA or a clinician. See the July 2026 peptide vote, explained.
Be careful here
A few issues are specific to women in this age group. Pregnancy is still possible during perimenopause, and unapproved peptides have no pregnancy safety data. Peptides that act on the growth hormone axis raise questions for anyone with a personal history of cancer, including breast cancer, which is one reason a full history matters. And heavy periods or new bleeding patterns deserve evaluation in their own right, not a supplement. Our article on who should not use peptide therapy covers more.
Matching the goal to the evidence
It can help to start from what you want to change rather than from a product.
- Hot flashes and night sweats: hormone therapy or an approved non-hormonal medicine, after a review of your risks.
- Sleep: treat night sweats if they are waking you, screen for sleep apnea, and address mood and anxiety; see sleep and mental health. The evidence for peptides and sleep is thin.
- Energy: check thyroid function, iron stores, blood sugar and sleep quality before anything else.
- Weight and shape: strength training and protein first; an approved GLP-1-based medicine if you meet the criteria and the trade-offs make sense.
- Skin: sunscreen and prescription retinoids have the best evidence; hormone therapy may also affect skin. Our skin and hair peptide guide compares the rest honestly.
- Desire: a proper assessment of physical, relational and hormonal causes, with bremelanotide as one option only if you are premenopausal and meet the criteria.
What a good consultation should cover
Whether you see us or someone else, a consultation worth having for these symptoms includes:
- a timeline of your symptoms and cycle changes;
- your full medical history, including cancer, clotting, heart disease, migraine and mental health;
- every medication and supplement you take;
- whether pregnancy is possible and what contraception you use;
- relevant labs, chosen for a reason;
- a frank discussion of the options with the best evidence, including those that aren't peptides and those that a telehealth clinic can't provide and would refer you for.
That last point is the test. A provider who only ever recommends what they sell isn't assessing you. Our peptide therapy consultations are set up to give you the full picture, including when the right answer is something other than a peptide, and you can book a consultation with a licensed clinician whenever you're ready.
Common questions
Can peptides help with perimenopause symptoms?
No peptide is FDA-approved to treat perimenopause or menopause symptoms such as hot flashes. Menopause hormone therapy and approved non-hormonal medicines have much stronger evidence. Some approved peptide medicines treat specific related conditions, such as osteoporosis or obesity, in women who meet the criteria.
Is PT-141 approved for women over 40?
Bremelanotide (Vyleesi) is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Age alone doesn't decide it; menopausal status does. It is not approved for postmenopausal women.
Are peptides a substitute for hormone therapy?
No. Unapproved peptides don't replace estrogen or progesterone and haven't been shown to relieve menopausal symptoms. If hormone therapy isn't right for you, there are other approved options to discuss.
Do I need blood tests to know if I'm in perimenopause?
Usually not to diagnose it, because hormone levels fluctuate too much for one test to be reliable. Blood tests are still useful to rule out other causes of symptoms, such as thyroid problems or iron deficiency, and before starting many medications.
Can I use peptides if I might become pregnant?
Unapproved peptides have no established pregnancy safety data, and some approved peptide medicines should be stopped before trying to conceive. If pregnancy is possible, tell your clinician before starting anything.
Talk to a licensed clinician
Reading about a treatment is not the same as knowing whether it fits your history. A consultation is a conversation about your own situation — not a sales call, and not a promise of any outcome.
Book a consultation
